68Ga PSMA-HBED-CC PET/CT in Imaging Patients with Metastatic Prostate Cancer

Inclusion Criteria

• Histological diagnosis of adenocarcinoma of the prostate OR has a clinical diagnosis of prostate cancer and on active therapy or has received treatment for prostate cancer
• Multifocal metastatic disease in either castrate sensitive or castrate resistant patients
• May or may not be on hormonal therapy, chemotherapy, or radium therapy; if on hormonal therapy or chemotherapy, must be on it for at least 3 months
• No plans to undergo prostate cancer (PCa) therapy (with hormone therapy, chemotherapy, radium therapy, or external radiation) between the two study exams
• At least 2 metastatic soft tissue or osseous lesions identified on conventional imaging (CT, magnetic resonance imaging [MRI] or bone scan)
• Karnofsky performance status of 50 or greater (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
• Ability to understand and willingness to sign a consent document

Exclusion Criteria

• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection requiring hospitalization, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Physical limitation that would limit compliance with the study requirements
• Current enrollment in a therapeutic clinical trial